Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a global leader in the medical devices industry, focused on tackling advanced stages of structural heart disease. With its strong presence in key products like surgical tissue heart valves and transcatheter aortic and mitral valve technologies, the company has established itself as the market leader. Its consistency in delivering positive earnings, focus on innovation, upcoming catalysts, and strong financial performance make it a promising investment with a positive outlook.

Bears say

Edwards Lifesciences is facing potential risks to its stock as its P/E multiple is above its peers, and its investments in salesforce, patient access initiatives, and awareness may not necessarily result in higher TAVR procedure volumes. Additionally, changes in CMS's national coverage determination may not necessarily be a positive tailwind for the company. Furthermore, there are potential risks such as competitive dynamics, failed R&D efforts, and macroeconomic challenges that could impact Edwards Lifesciences' performance and stock price.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.